Supplementary Figure S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Puntos clave
MAIN FINDING: The study presents the first-in-class cdk2/4/6 inhibitor PF-06873600 in relation to breast cancer.
KEY EVIDENCE: Median ctDNA change alongside progression-free survival (PFS) was assessed in treated patients.
APPROACH: This phase I/IIa study evaluated the drug alone and in combination with endocrine therapy.
SIGNIFICANCE: Findings suggest the potential of PF-06873600 to enhance treatment strategies for breast cancer.
Resumen
Supplementary Figure S3. Median ctDNA change and PFS.
Me gusta
Guardar
Compartir
Me gusta
Guardar
Compartir
Supplementary Figure S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer | Synapse